Biologics are pharmaceutical products derived from living cells or micro-organisms. These are complex and large molecules comprising of proteins, peptides, nucleic acids, sugars, cellular structures or a combination of all the above. The biologics drug discovery process involves target identification, hit-to-lead stage, lead identification & optimization. Technologies applied for the development of biologics include genomics, proteomics, microarrays, cell cultures, phage display technologies and monoclonal antibody technologies. Biologics include genes that control production of vital proteins; proteins that control the action of other proteins and cellular processes; and modify human hormones or cells that produce products that suppress or activate the components of the immune system. They are used for the treatment of various diseases such as rheumatoid arthritis, ulcerative colitis, and other autoimmune diseases. The common side effects of biologics drugs observed are weakness, chills, allergic reactions, nausea, diarrhoea, itching, vomiting, injection side reaction, constipation, cough, headache, fever, shortness of breath, fever, dizziness, and others. The major biologics drugs presently available in the market are Humira, Remicade, Enbrel, Avastin and Herceptin. The Biologics Market is projected to reach USD 559.6 billion by 2030 from USD 274.1 billion in 2020, at an approximate CAGR of 7.40%.

Market Segmentation:

On the basis of source type, the biologics market can be classified into microbial, mammalian, and others. Based on product type, the market can be segmented into monoclonal antibody, interleukins, vaccines, growth factors, gene therapy, and others. According to disease indication, the biologics market can be categorised into immunological disorders, cardiovascular disorders, haematological disorders, cancer, arthritis, diabetes, and others. Geographically, the global biologics market can be broadly divided into five regions mainly North America, Europe, Asia Pacific, and RoW.

Market Dynamics and Factors:

Rising prevalence of chronic diseases, incessant research and development activities, and continuous investment in biologics are the major factors attributing to the market growth of the biologics market across the globe. For instance, according to the World Health Organization (WHO), by 2020 chronic diseases would constitute around 75% of the total deaths worldwide.  Cancer, autoimmune diseases, and diabetes attribute to almost 60% of the overall biologics market. In 2016, approximately 50% of the new molecular units approved by the Food and Drug Administration were biologics. Continuous advancements in cellular & gene therapy further catalyses the market because of its high efficacy and therapeutic outcome. Furthermore, other major factors such as rising expenditure on healthcare, increased availability of advanced diagnostics, and growing applications of monoclonal antibodies for the treatment of different diseases are also positively impacting the overall growth of the global biologics market. However, certain factors like the emergence of biosimilars, high cost of biologics, lack of oral absorption and operational challenges are restraining the market growth of the global biologics market.

Geographic Analysis:

North America is expected to dominate the global biologics market in terms of market share during the forecast period. The presence of key market players, continuous R&D in the biologics field, growing prevalence of chronic disorders, and longer patent protection compared to other regions are the major factors attributing to the market dominance of the region. For instance, U.S. pharmaceutical companies’ account for almost 80% of the world’s R&D in health care biotechnology. The Asia Pacific region is anticipated to witness the fastest growth in the biologics market during the forecast period. Expansion of international players in developing nations contribute to the biologics market growth in the APAC region. For instance, Novartis AG wishes to launch its FDA approved treatment Kymriah in Japan. Additionally, there has been a spurt of heavy investments by Asian contract manufacturers in order to grab share in the global biologics market. Companies such as Samsung Biologics and Wuxi Biologics are anticipated to drive the market growth in the Asian region.     

Competitive Scenario:

The key players operating in the global biologics market are –

AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG, Sanofi, Hoffman La-Roche, Samsung Biologics, Eli Lilly & Company, Merck & Co., Johnson & Johnson Services Inc.   

Biologics Market Report Scope